<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361502</url>
  </required_header>
  <id_info>
    <org_study_id>MIRACLE</org_study_id>
    <nct_id>NCT02361502</nct_id>
  </id_info>
  <brief_title>MIrabegron With oveRACtive bLadder Symptoms in mEn</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The proportion of male patients who participated in the phase III study of mirabegron was
      about 28% and the data on the efficacy and safety of mirabegron in Korean male OAB patients
      have limits. For this reason, this study will assess the efficacy and safety of mirabegron in
      Korean male OAB patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 50 to 75% of men with LUTS secondary to BPH also have overactive bladder symptoms. As a
      major drug for the treatment of overactive bladder symptoms, muscarinic receptor antagonists
      are used, but precautions should be taken by a specialist when using muscarinic receptor
      antagonists due to possibilities of dry mouth, constipation, blurred vision and post-dose
      dysuria and acute ischuria. Mirabegron is a selective β3-adrenoceptor agonist that relax the
      detrusor smooth muscle and increase functional bladder capacity to improve overactive bladder
      symptoms. This study will examine the efficacy and safety of mirabegron, a new drug, for
      improvement of urinary frequency.

      The efficacy of mirabegron compared to the placebo has been demonstrated by the phase III
      study, but the analysis of only patients in Korea has not obtained significant difference
      from the placebo. The prevalence of overactive bladder was 9.7% in men and 11.6% in women,
      which showed similar rates 1), but the cure rate is higher in men than in women (OR 1.891, CI
      1.362, 2.2627, p=0.0001). Male patients are important customers for the OAB market and
      low-dose anticholinergic agents with relatively low risk of urinary retention are preferred
      for the treatment of male overactive bladder (OAB) in Korea. We will conduct this clinical
      study because we think mirabegron will be an alternative for the therapy for male OAB
      patients with a risk of urinary retention.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean number of micturitions per 24 hours</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of urgency episodes per 24 hours</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of urgency incontinence episodes per 24 hours</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a total of OABSS</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in residual volume and maximal urinary flow rate</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IPSS storage subscore</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IPSS-QOL symptom score</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events of study drug</measure>
    <time_frame>after 12 and 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>mirabegron placebo qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron 50mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <arm_group_label>mirabegron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 20 years

          -  Patients with an average of at least 8 micturitions per 24 hours in last 3 days based
             on the micturition diary

          -  Patients with an average of at least 1 episode of urgency per 24 hours in last 3 days
             based on the micturition diary

          -  Patients who have symptoms of OAB for at least 12 weeks prior to the enrollment

          -  Patients who are able to complete the micturition diary and questionnaires correctly

          -  Patients who provided a singed consent form after being informed of the nature of the
             study and risk and benefit of the study treatment.

        Exclusion Criteria:

          -  Patients with AUR history

          -  Patients with PSA ≥ 10 ng/ml or suspected prostate cancer

          -  Patients who have an average total daily urine volume ≥ 3000 mL

          -  Patients with suspected stress incontinence

          -  Patients with PVR ≥200 ml or Qmax ≤5ml/sec

          -  Patients who have used according to the criteria below:

               -  Patients who began or discontinued the drug(s) or changed the dose within 4 weeks
                  before enrollment

               -  Patients who were treated with an anticholinergic agent, 5-aplha reductase
                  inhibitor within 4 weeks before enrollment

               -  Patients who began or discontinued 5ARI treatment or changed the dose within 6
                  months

          -  Patients began or has changed a bladder training program or pelvic floor exercises
             less than 4 weeks prior to Screening.

          -  Patients who had an indwelling catheter or practices intermittent self-catheterization

          -  Patients who received surgical treatment that may influence urinary track function
             (TURP, laser therapy, etc.) within 24 weeks of run-in period

          -  Uncontrolled hypertension: SBP ≥180 mmHg, DBP ≥110 mmHg

          -  Pulse rate ≥110 bmp or &lt;50 bpm

          -  Patients with complications of urinary tract infection, urolithiasis and interstitial
             cystitis or past history of recurrent urinary tract infection

          -  Patients with hypersensitivity to β-adrenergic receptor agonists or anticholinergics

          -  Patients has a clinically significant ECG abnormality, as determined by the
             Investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soo Woong Kim, M.D., Ph.D.</last_name>
    <phone>+82-2-2072-2426</phone>
    <email>swkim@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Ho Kim</last_name>
      <phone>82-10-2975-3262</phone>
      <email>yhkuro@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Ho Kim, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Jin Jeong, MD</last_name>
      <email>urojsj@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Seong-Jin Jeong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hyun Bae, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jae Hyun Bae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Gil Shin, Ph.D.</last_name>
      <phone>82-51-240-7351</phone>
      <email>shindong16@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Dong Gil Shin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung kook University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Sang Yoo, MD</last_name>
      <email>uroyoo@knu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun Sang Yoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Hyo Woo, MD, PH D</last_name>
      <email>woosing@eulji.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung Hyo Woo, MD, PH D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ga-cheon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang jin yoon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sang jin yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheonnam University Hospital</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Wook Kang, MD, PH D</last_name>
      <email>sydad@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Tae Wook Kang, MD, PH D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Woong Kim, M.D., Ph.D.</last_name>
      <phone>+82-2-2072-2426</phone>
      <email>swkim@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Soo Woong Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Gab Jeong, MD, PhD</last_name>
      <email>igjeong@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>In Gab Jeong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Su Cho, MD</last_name>
      <email>kscho99@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Kang Su Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Goo Lee, MD</last_name>
      <email>uroyglee@nate.com</email>
    </contact>
    <investigator>
      <last_name>Young-Goo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kang book Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwan joong Joo, MD, PhD</last_name>
      <email>urojoo@dreamwiz.com</email>
    </contact>
    <investigator>
      <last_name>Kwan joong Joo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang jin yoon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sang jin yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hwan Cheol Son, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hwan Cheol Son, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo Woong Kim, MD</investigator_full_name>
    <investigator_title>Seoul National University Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

